It\u2019s not just Americans who like keeping tabs on their wellbeing. Japanese toilet maker Toto has been testing users\u2019 urine for diabetes and other conditions for decades. Prissier westerners prefer trackers around their wrists or, in the case of the \u014cura ring, fingers. In China, the biggest smartwatch market, according to IDC<\/a>, homegrown Huawei leads the field, a surprise since a former boss once professed himself pessimistic about the market.<\/p>\n Picking winners can be tricky, especially when politicians are involved in deciding whose technologies work best. The medical market has a tendency to breed cronyism, as the UK discovered during the pandemic. Donald Trump\u2019s administration has been unabashed about backing individual businesses.<\/p>\n Dexcom is one that already moves in the right circles, at least. It has partnered with health-monitoring company Levels, co-founded by Casey Means \u2014 Trump\u2019s pick to be US surgeon general<\/a> and a fan of Kennedy. Moreover, it has already laid the groundwork for potentially useful industry collaborations: Dexcom backed \u014cura\u2019s\u00a0$200mn fundraising<\/a> at the end of last year.\u00a0<\/p>\n Snafus, from data breaches to privacy violations, are inevitable. There is a graveyard of medical ventures that have sought to empower users, from blood-testing start-up Theranos to Microsoft\u2019s healthcare data storage HealthVault, which was shuttered in 2019<\/a>. Others have simply shrunk, such as Fitbit, for which Google paid $2.1bn<\/a> in 2019, roughly half the value at which it went public four years previously.<\/p>\n Dexcom itself is increasing revenue at a decent clip; consensus forecasts are for a 20 per cent increase in patients this year and 15 per cent next year. But demand is tricky to forecast. The shares, and performance, have been volatile. It doesn\u2019t help when new rivals regularly spring up with tempting deals \u2014 Zoe in the UK, which offers in-home test kits and personalised nutrition plans, is an example.<\/p>\n As for the obvious risk of becoming a fad, tech companies already embedded in people\u2019s lives \u2014 and recipients of much of their data \u2014 have the best chance, as Apple and Huawei show. But even that is not a given. Google, without hardware in its DNA, has shed monthly active Fitbit users in recent years, according<\/a> to the Business of Apps.<\/p>\n The eternal challenge for such ideas is that the path of least resistance is often seen as treatment rather than prevention. For weight loss, for example, bariatric surgery has ceded ground to GLP-1 injections. And besides, monitoring is only valuable if the user acts on what they learn. Kennedy, like so many wearable device buyers, may be starting with good intentions. If only that were enough. <\/p>\n![\"Line](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/06\/https:\/\/d6c748xw2pzm8.cloudfront.net\/prod\/07305930-5291-11f0-9dcd-e755e96d6b16-standard.png\")
<\/p>\n